Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | APAF1 | O14727 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | XBP1 | P17861 | 1/20 | 0.45 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | GALK1 | P51570 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6042142 | 0.88 | NOTUM (0.77) | NOTUMFKBP5L3MBTL1NSD2ABL1 | |
| SCHEMBL18656032 | 0.79 | NOTUM (0.66) | NOTUMNPC1L3MBTL1MAPTRAB9A | |
| SCHEMBL2876314 | 0.79 | NOTUM (0.66) | NOTUMNPC1L3MBTL1NSD2ABL1 | |
| SCHEMBL22585011 | 0.79 | NOTUM (0.64) | NOTUML3MBTL1NSD2ABL1PPARG | |
| SCHEMBL3476831 | 0.78 | NOTUM (0.64) | NOTUMMAPTTHRBKDM4EGAA | |
| SCHEMBL6042144 | 0.78 | NOTUM (0.64) | NOTUMMAPTTHRBMEN1LMNA | |
| SCHEMBL3901501 | 0.78 | NOTUM (0.64) | NOTUMTDP1ALDH2TDP2MAP4K4 | |
| SCHEMBL4231200 | 0.78 | NOTUM (0.64) | NOTUMMAPTALDH2TNKS2MAP4K4 | |
| SCHEMBL94548 | 0.78 | NOTUM (0.64) | NOTUMMEN1LMNAKMT2AALDH2 | |
| SCHEMBL29891077 | 0.78 | NOTUM (0.64) | NOTUMNPC1L3MBTL1MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313295-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | Almac Discovery Limited (GB) | 2024-02-07 | — | — | EP | claimed |
| CN-117157285-A | Pharmaceutical compounds as ubiquitin-specific protease 19 (USP 19) inhibitors | 阿尔麦克探索有限公司 | 2023-12-01 | — | — | CN | claimed |
| WO-2022200523-A9 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2023-02-16 | — | — | WO | claimed |
| WO-2022200523-A1 | PHARMACEUTICALS COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2022-09-29 | — | — | WO | claimed |
| EP-0603649-B1 | Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridines as HMG-CoA reductase inhibitors | BAYER AG (DE) | 1996-07-10 | — | — | EP | claimed |
| CN-1117965-A | Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridines | BAYER AG (DE) | 1996-03-06 | — | — | CN | claimed |
| US-5418243-A | Anticholesterol agents | BAYER AKTIENGESELLSCHAFT (DE) | 1995-05-23 | — | — | US | claimed |
| EP-0603649-A1 | Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridines as HMG-CoA reductase inhibitors | BAYER AG (DE) | 1994-06-29 | — | — | EP | claimed |
| US-12466805-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2025-11-11 | — | — | US | disclosed |
| US-20240327382-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 | ALMAC DISCOVERY LIMITED (GB) | 2024-10-03 | — | — | US | disclosed |
| CN-118666740-A | Synthesis of surface chiral [2.2] cyclopyridine/lactam compound by parallel kinetic resolution and preparation method thereof | 贵州大学 | 2024-09-20 | — | — | CN | disclosed |
| US-20240217979-A1 | GluN2 Subunit Selective Antagonists of the N-Methyl-D-Aspartate Receptors | UNIV EMORY (US) | 2024-07-04 | — | — | US | disclosed |
| EP-4313295-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | Almac Discovery Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| CN-117157285-A | Pharmaceutical compounds as ubiquitin-specific protease 19 (USP 19) inhibitors | 阿尔麦克探索有限公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-0603649-A1 | Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridines as HMG-CoA reductase inhibitors | BAYER AG (DE) | 1994-06-29 | — | — | EP | disclosed |
| EP-0603649-A1 | Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridines as HMG-CoA reductase inhibitors | BAYER AG (DE) | 1994-06-29 | — | — | EP | disclosed |
| EP-0540604-A1 | SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | Aventis Pharma S.A. (FR) | 1993-05-12 | — | — | EP | disclosed |
| US-5189047-A | Useful in the treament of respiratory track disorder, hypertension and bronchodilator activity or utility as potassium channel activator | BEECHAM GROUP P.L.C. (GB) | 1993-02-23 | — | — | US | disclosed |
| WO-1992001675-A2 | SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | RHONE-POULENC RORER S.A. (FR) | 1992-02-06 | — | — | WO | disclosed |
| EP-0413438-A1 | Benzopyran compounds | Beecham Group p.l.c. (GB) | 1991-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327382-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 | USP19, USP18, UBE2I | NOTUM 1050/4885NPC1 686/4885FKBP5 1195/4885 |
| US-12466805-B2 | Pharmaceutical compounds | USP19, USP18, UBE2I | NOTUM 834/4885NPC1 457/4885FKBP5 1524/4885 |
| US-20240217979-A1 | GluN2 Subunit Selective Antagonists of the N-Methyl-D-Aspartate Receptors | GRIN2B, GRIN2A, GRIN2C | NOTUM 4588/4885NPC1 3579/4885FKBP5 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.